Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Mar;65(3):311–320. doi: 10.1038/bjc.1992.65

Insulin-like growth factors and cancer.

V M Macaulay 1
PMCID: PMC1977607  PMID: 1313689

Full text

PDF
311

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arteaga C. L., Kitten L. J., Coronado E. B., Jacobs S., Kull F. C., Jr, Allred D. C., Osborne C. K. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989 Nov;84(5):1418–1423. doi: 10.1172/JCI114315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arteaga C. L., Kitten L. J., Coronado E. B., Jacobs S., Kull F. C., Jr, Allred D. C., Osborne C. K. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989 Nov;84(5):1418–1423. doi: 10.1172/JCI114315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arteaga C. L., Osborne C. K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989 Nov 15;49(22):6237–6241. [PubMed] [Google Scholar]
  4. Arteaga C. L., Osborne C. K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989 Nov 15;49(22):6237–6241. [PubMed] [Google Scholar]
  5. Axelrod L., Ron D. Insulin-like growth factor II and the riddle of tumor-induced hypoglycemia. N Engl J Med. 1988 Dec 1;319(22):1477–1479. doi: 10.1056/NEJM198812013192209. [DOI] [PubMed] [Google Scholar]
  6. Axelrod L., Ron D. Insulin-like growth factor II and the riddle of tumor-induced hypoglycemia. N Engl J Med. 1988 Dec 1;319(22):1477–1479. doi: 10.1056/NEJM198812013192209. [DOI] [PubMed] [Google Scholar]
  7. Bagley C. J., May B. L., Szabo L., McNamara P. J., Ross M., Francis G. L., Ballard F. J., Wallace J. C. A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide. Biochem J. 1989 May 1;259(3):665–671. doi: 10.1042/bj2590665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bagley C. J., May B. L., Szabo L., McNamara P. J., Ross M., Francis G. L., Ballard F. J., Wallace J. C. A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide. Biochem J. 1989 May 1;259(3):665–671. doi: 10.1042/bj2590665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Barreca A., Minuto F. Somatomedins: chemical and functional characteristics of the different molecular forms. J Endocrinol Invest. 1989 Apr;12(4):279–293. doi: 10.1007/BF03349988. [DOI] [PubMed] [Google Scholar]
  10. Barreca A., Minuto F. Somatomedins: chemical and functional characteristics of the different molecular forms. J Endocrinol Invest. 1989 Apr;12(4):279–293. doi: 10.1007/BF03349988. [DOI] [PubMed] [Google Scholar]
  11. Baxter R. C. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab. 1988 Aug;67(2):265–272. doi: 10.1210/jcem-67-2-265. [DOI] [PubMed] [Google Scholar]
  12. Baxter R. C. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab. 1988 Aug;67(2):265–272. doi: 10.1210/jcem-67-2-265. [DOI] [PubMed] [Google Scholar]
  13. Biddle C., Li C. H., Schofield P. N., Tate V. E., Hopkins B., Engstrom W., Huskisson N. S., Graham C. F. Insulin-like growth factors and the multiplication of Tera-2, a human teratoma-derived cell line. J Cell Sci. 1988 Jul;90(Pt 3):475–484. doi: 10.1242/jcs.90.3.475. [DOI] [PubMed] [Google Scholar]
  14. Biddle C., Li C. H., Schofield P. N., Tate V. E., Hopkins B., Engstrom W., Huskisson N. S., Graham C. F. Insulin-like growth factors and the multiplication of Tera-2, a human teratoma-derived cell line. J Cell Sci. 1988 Jul;90(Pt 3):475–484. doi: 10.1242/jcs.90.3.475. [DOI] [PubMed] [Google Scholar]
  15. Blatt J., White C., Dienes S., Friedman H., Foley T. P., Jr Production of an insulin-like growth factor by osteosarcoma. Biochem Biophys Res Commun. 1984 Aug 30;123(1):373–376. doi: 10.1016/0006-291x(84)90423-6. [DOI] [PubMed] [Google Scholar]
  16. Blatt J., White C., Dienes S., Friedman H., Foley T. P., Jr Production of an insulin-like growth factor by osteosarcoma. Biochem Biophys Res Commun. 1984 Aug 30;123(1):373–376. doi: 10.1016/0006-291x(84)90423-6. [DOI] [PubMed] [Google Scholar]
  17. Brice A. L., Cheetham J. E., Bolton V. N., Hill N. C., Schofield P. N. Temporal changes in the expression of the insulin-like growth factor II gene associated with tissue maturation in the human fetus. Development. 1989 Jul;106(3):543–554. doi: 10.1242/dev.106.3.543. [DOI] [PubMed] [Google Scholar]
  18. Brice A. L., Cheetham J. E., Bolton V. N., Hill N. C., Schofield P. N. Temporal changes in the expression of the insulin-like growth factor II gene associated with tissue maturation in the human fetus. Development. 1989 Jul;106(3):543–554. doi: 10.1242/dev.106.3.543. [DOI] [PubMed] [Google Scholar]
  19. Cariani E., Lasserre C., Seurin D., Hamelin B., Kemeny F., Franco D., Czech M. P., Ullrich A., Brechot C. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 1988 Dec 1;48(23):6844–6849. [PubMed] [Google Scholar]
  20. Cariani E., Lasserre C., Seurin D., Hamelin B., Kemeny F., Franco D., Czech M. P., Ullrich A., Brechot C. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 1988 Dec 1;48(23):6844–6849. [PubMed] [Google Scholar]
  21. Caro J. F., Poulos J., Ittoop O., Pories W. J., Flickinger E. G., Sinha M. K. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest. 1988 Apr;81(4):976–981. doi: 10.1172/JCI113451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Caro J. F., Poulos J., Ittoop O., Pories W. J., Flickinger E. G., Sinha M. K. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest. 1988 Apr;81(4):976–981. doi: 10.1172/JCI113451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Cascieri M. A., Chicchi G. G., Applebaum J., Hayes N. S., Green B. G., Bayne M. L. Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor. Biochemistry. 1988 May 3;27(9):3229–3233. doi: 10.1021/bi00409a016. [DOI] [PubMed] [Google Scholar]
  24. Cascieri M. A., Chicchi G. G., Applebaum J., Hayes N. S., Green B. G., Bayne M. L. Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor. Biochemistry. 1988 May 3;27(9):3229–3233. doi: 10.1021/bi00409a016. [DOI] [PubMed] [Google Scholar]
  25. Cascieri M. A., Saperstein R., Hayes N. S., Green B. G., Chicchi G. G., Applebaum J., Bayne M. L. Serum half-life and biological activity of mutants of human insulin-like growth factor I which do not bind to serum binding proteins. Endocrinology. 1988 Jul;123(1):373–381. doi: 10.1210/endo-123-1-373. [DOI] [PubMed] [Google Scholar]
  26. Cascieri M. A., Saperstein R., Hayes N. S., Green B. G., Chicchi G. G., Applebaum J., Bayne M. L. Serum half-life and biological activity of mutants of human insulin-like growth factor I which do not bind to serum binding proteins. Endocrinology. 1988 Jul;123(1):373–381. doi: 10.1210/endo-123-1-373. [DOI] [PubMed] [Google Scholar]
  27. Cavailles V., Garcia M., Rochefort H. Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol Endocrinol. 1989 Mar;3(3):552–558. doi: 10.1210/mend-3-3-552. [DOI] [PubMed] [Google Scholar]
  28. Cavailles V., Garcia M., Rochefort H. Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol Endocrinol. 1989 Mar;3(3):552–558. doi: 10.1210/mend-3-3-552. [DOI] [PubMed] [Google Scholar]
  29. Chen Z. Z., Schwartz G. P., Zong L., Burke G. T., Chanley J. D., Katsoyannis P. G. Determinants of growth-promoting activity reside in the A-domain of insulin-like growth factor I. Biochemistry. 1988 Aug 9;27(16):6105–6111. doi: 10.1021/bi00416a041. [DOI] [PubMed] [Google Scholar]
  30. Chen Z. Z., Schwartz G. P., Zong L., Burke G. T., Chanley J. D., Katsoyannis P. G. Determinants of growth-promoting activity reside in the A-domain of insulin-like growth factor I. Biochemistry. 1988 Aug 9;27(16):6105–6111. doi: 10.1021/bi00416a041. [DOI] [PubMed] [Google Scholar]
  31. Clemmons D. R., Van Wyk J. J. Somatomedin-C and platelet-derived growth factor stimulate human fibroblast replication. J Cell Physiol. 1981 Mar;106(3):361–367. doi: 10.1002/jcp.1041060305. [DOI] [PubMed] [Google Scholar]
  32. Clemmons D. R., Van Wyk J. J. Somatomedin-C and platelet-derived growth factor stimulate human fibroblast replication. J Cell Physiol. 1981 Mar;106(3):361–367. doi: 10.1002/jcp.1041060305. [DOI] [PubMed] [Google Scholar]
  33. Colletti R. B., Roberts J. D., Devlin J. T., Copeland K. C. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res. 1989 Apr 1;49(7):1882–1884. [PubMed] [Google Scholar]
  34. Colletti R. B., Roberts J. D., Devlin J. T., Copeland K. C. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res. 1989 Apr 1;49(7):1882–1884. [PubMed] [Google Scholar]
  35. Czech M. P. Signal transmission by the insulin-like growth factors. Cell. 1989 Oct 20;59(2):235–238. doi: 10.1016/0092-8674(89)90281-x. [DOI] [PubMed] [Google Scholar]
  36. Czech M. P. Signal transmission by the insulin-like growth factors. Cell. 1989 Oct 20;59(2):235–238. doi: 10.1016/0092-8674(89)90281-x. [DOI] [PubMed] [Google Scholar]
  37. D'Ercole A. J., Stiles A. D., Underwood L. E. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A. 1984 Feb;81(3):935–939. doi: 10.1073/pnas.81.3.935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Daughaday W. H., Emanuele M. A., Brooks M. H., Barbato A. L., Kapadia M., Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988 Dec 1;319(22):1434–1440. doi: 10.1056/NEJM198812013192202. [DOI] [PubMed] [Google Scholar]
  39. Daughaday W. H., Emanuele M. A., Brooks M. H., Barbato A. L., Kapadia M., Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988 Dec 1;319(22):1434–1440. doi: 10.1056/NEJM198812013192202. [DOI] [PubMed] [Google Scholar]
  40. Daughaday W. H., Hall K., Salmon W. D., Jr, Van den Brande J. L., Van Wyk J. J. On the nomenclature of the somatomedins and insulin-like growth factors. J Clin Endocrinol Metab. 1987 Nov;65(5):1075–1076. doi: 10.1210/jcem-65-5-1075. [DOI] [PubMed] [Google Scholar]
  41. Daughaday W. H., Hall K., Salmon W. D., Jr, Van den Brande J. L., Van Wyk J. J. On the nomenclature of the somatomedins and insulin-like growth factors. J Clin Endocrinol Metab. 1987 Nov;65(5):1075–1076. doi: 10.1210/jcem-65-5-1075. [DOI] [PubMed] [Google Scholar]
  42. Daughaday W. H., Kapadia M. Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6778–6782. doi: 10.1073/pnas.86.17.6778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Daughaday W. H., Kapadia M. Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6778–6782. doi: 10.1073/pnas.86.17.6778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Daughaday W. H. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology. 1990 Jul;127(1):1–4. doi: 10.1210/endo-127-1-1. [DOI] [PubMed] [Google Scholar]
  45. Daughaday W. H., Wu J. C., Lee S. D., Kapadia M. Abnormal processing of pro-IGF-II in patients with hepatoma and in some hepatitis B virus antibody-positive asymptomatic individuals. J Lab Clin Med. 1990 Oct;116(4):555–562. [PubMed] [Google Scholar]
  46. Davenport M. L., D'Ercole A. J., Azizkhan J. C., Lund P. K. Somatomedin-C/insulinlike growth factor I (Sm-C/IGF-I) and insulinlike growth factor II (IGF-II) mRNAs during lung development in the rat. Exp Lung Res. 1988;14(5):607–618. doi: 10.3109/01902148809087832. [DOI] [PubMed] [Google Scholar]
  47. Dawson-Hughes B., Stern D., Goldman J., Reichlin S. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab. 1986 Aug;63(2):424–432. doi: 10.1210/jcem-63-2-424. [DOI] [PubMed] [Google Scholar]
  48. De Larco J. E., Tadaro G. J. A human fibrosarcoma cell line producing multiplication stimulating activity (MSA)-related peptides. Nature. 1978 Mar 23;272(5651):356–358. doi: 10.1038/272356a0. [DOI] [PubMed] [Google Scholar]
  49. De Leon D. D., Wilson D. M., Bakker B., Lamsom G., Hintz R. L., Rosenfeld R. G. Characterization of insulin-like growth factor binding proteins from human breast cancer cells. Mol Endocrinol. 1989 Mar;3(3):567–574. doi: 10.1210/mend-3-3-567. [DOI] [PubMed] [Google Scholar]
  50. Dickson R. B., Kasid A., Huff K. K., Bates S. E., Knabbe C., Bronzert D., Gelmann E. P., Lippman M. E. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A. 1987 Feb;84(3):837–841. doi: 10.1073/pnas.84.3.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Dickson R. B., McManaway M. E., Lippman M. E. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science. 1986 Jun 20;232(4757):1540–1543. doi: 10.1126/science.3715461. [DOI] [PubMed] [Google Scholar]
  52. Dulak N. C., Temin H. M. A partially purified polypeptide fraction from rat liver cell conditioned medium with multiplication-stimulating activity for embryo fibroblasts. J Cell Physiol. 1973 Apr;81(2):153–160. doi: 10.1002/jcp.1040810204. [DOI] [PubMed] [Google Scholar]
  53. El-Badry O. M., Helman L. J., Chatten J., Steinberg S. M., Evans A. E., Israel M. A. Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest. 1991 Feb;87(2):648–657. doi: 10.1172/JCI115042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. El-Badry O. M., Romanus J. A., Helman L. J., Cooper M. J., Rechler M. M., Israel M. A. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest. 1989 Sep;84(3):829–839. doi: 10.1172/JCI114243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. FROESCH E. R., BUERGI H., RAMSEIER E. B., BALLY P., LABHART A. ANTIBODY-SUPPRESSIBLE AND NONSUPPRESSIBLE INSULIN-LIKE ACTIVITIES IN HUMAN SERUM AND THEIR PHYSIOLOGIC SIGNIFICANCE. AN INSULIN ASSAY WITH ADIPOSE TISSUE OF INCREASED PRECISION AND SPECIFICITY. J Clin Invest. 1963 Nov;42:1816–1834. doi: 10.1172/JCI104866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Fagin J. A., Melmed S. Relative increase in insulin-like growth factor I messenger ribonucleic acid levels in compensatory renal hypertrophy. Endocrinology. 1987 Feb;120(2):718–724. doi: 10.1210/endo-120-2-718. [DOI] [PubMed] [Google Scholar]
  57. Foekens J. A., Portengen H., Janssen M., Klijn J. G. Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer. 1989 Jun 1;63(11):2139–2147. doi: 10.1002/1097-0142(19890601)63:11<2139::aid-cncr2820631112>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  58. Freed K. A., Herington A. C. Insulin-like growth factor-I and its autocrine role in growth of MCF-7 human breast cancer cells in culture. J Mol Endocrinol. 1989 Nov;3(3):183–190. doi: 10.1677/jme.0.0030183. [DOI] [PubMed] [Google Scholar]
  59. Froesch E. R., Zapf J. Insulin-like growth factors and insulin: comparative aspects. Diabetologia. 1985 Aug;28(8):485–493. doi: 10.1007/BF00281982. [DOI] [PubMed] [Google Scholar]
  60. Furlanetto R. W., DiCarlo J. N. Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res. 1984 May;44(5):2122–2128. [PubMed] [Google Scholar]
  61. Gansler T., Furlanetto R., Gramling T. S., Robinson K. A., Blocker N., Buse M. G., Sens D. A., Garvin A. J. Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. Am J Pathol. 1989 Dec;135(6):961–966. [PMC free article] [PubMed] [Google Scholar]
  62. Glick R. P., Gettleman R., Patel K., Lakshman R., Tsibris J. C. Insulin and insulin-like growth factor I in brain tumors: binding and in vitro effects. Neurosurgery. 1989 Jun;24(6):791–797. doi: 10.1227/00006123-198906000-00001. [DOI] [PubMed] [Google Scholar]
  63. Gloudemans T., Prinsen I., Van Unnik J. A., Lips C. J., Den Otter W., Sussenbach J. S. Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res. 1990 Oct 15;50(20):6689–6695. [PubMed] [Google Scholar]
  64. Goldstein R. H., Poliks C. F., Pilch P. F., Smith B. D., Fine A. Stimulation of collagen formation by insulin and insulin-like growth factor I in cultures of human lung fibroblasts. Endocrinology. 1989 Feb;124(2):964–970. doi: 10.1210/endo-124-2-964. [DOI] [PubMed] [Google Scholar]
  65. Guler H. P., Zapf J., Froesch E. R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med. 1987 Jul 16;317(3):137–140. doi: 10.1056/NEJM198707163170303. [DOI] [PubMed] [Google Scholar]
  66. Guler H. P., Zapf J., Schmid C., Froesch E. R. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989 Dec;121(6):753–758. doi: 10.1530/acta.0.1210753. [DOI] [PubMed] [Google Scholar]
  67. Han V. K., D'Ercole A. J., Lund P. K. Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science. 1987 Apr 10;236(4798):193–197. doi: 10.1126/science.3563497. [DOI] [PubMed] [Google Scholar]
  68. Hartshorn M. A., Scott C. D., Baxter R. C. Immunofluorescent localization of type II insulin-like growth factor receptor in rat liver and hepatoma cells. J Endocrinol. 1989 May;121(2):221–227. doi: 10.1677/joe.0.1210221. [DOI] [PubMed] [Google Scholar]
  69. Haselbacher G. K., Irminger J. C., Zapf J., Ziegler W. H., Humbel R. E. Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms tumors: expression at the mRNA and protein level. Proc Natl Acad Sci U S A. 1987 Feb;84(4):1104–1106. doi: 10.1073/pnas.84.4.1104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Heath J. K., Shi W. K. Developmentally regulated expression of insulin-like growth factors by differentiated murine teratocarcinomas and extraembryonic mesoderm. J Embryol Exp Morphol. 1986 Jun;95:193–212. [PubMed] [Google Scholar]
  71. Heaton J. H., Krett N. L., Gelehrter T. D. Regulation of insulin and insulin-like growth factor (IGF) responsiveness by IGFs in rat hepatoma cells. Endocrinology. 1986 Jun;118(6):2555–2560. doi: 10.1210/endo-118-6-2555. [DOI] [PubMed] [Google Scholar]
  72. Henry I., Bonaiti-Pellié C., Chehensse V., Beldjord C., Schwartz C., Utermann G., Junien C. Uniparental paternal disomy in a genetic cancer-predisposing syndrome. Nature. 1991 Jun 20;351(6328):665–667. doi: 10.1038/351665a0. [DOI] [PubMed] [Google Scholar]
  73. Holly J. M., Wass J. A. Insulin-like growth factors; autocrine, paracrine or endocrine? New perspectives of the somatomedin hypothesis in the light of recent developments. J Endocrinol. 1989 Sep;122(3):611–618. doi: 10.1677/joe.0.1220611. [DOI] [PubMed] [Google Scholar]
  74. Hossenlopp P., Seurin D., Segovia-Quinson B., Hardouin S., Binoux M. Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem. 1986 Apr;154(1):138–143. doi: 10.1016/0003-2697(86)90507-5. [DOI] [PubMed] [Google Scholar]
  75. Huff K. K., Kaufman D., Gabbay K. H., Spencer E. M., Lippman M. E., Dickson R. B. Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res. 1986 Sep;46(9):4613–4619. [PubMed] [Google Scholar]
  76. Huff K. K., Knabbe C., Lindsey R., Kaufman D., Bronzert D., Lippman M. E., Dickson R. B. Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells. Mol Endocrinol. 1988 Mar;2(3):200–208. doi: 10.1210/mend-2-3-200. [DOI] [PubMed] [Google Scholar]
  77. Humbel R. E. Insulin-like growth factors I and II. Eur J Biochem. 1990 Jul 5;190(3):445–462. doi: 10.1111/j.1432-1033.1990.tb15595.x. [DOI] [PubMed] [Google Scholar]
  78. Irminger J. C., Schoenle E. J., Briner J., Humbel R. E. Structural alteration of the insulin-like growth factor II-gene in Wilms tumour. Eur J Pediatr. 1989 Jun;148(7):620–623. doi: 10.1007/BF00441514. [DOI] [PubMed] [Google Scholar]
  79. Jaques G., Kiefer P., Rotsch M., Hennig C., Göke R., Richter G., Havemann K. Production of insulin-like growth factor binding proteins by small-cell lung cancer cell lines. Exp Cell Res. 1989 Oct;184(2):396–406. doi: 10.1016/0014-4827(89)90339-x. [DOI] [PubMed] [Google Scholar]
  80. Jaques G., Rotsch M., Wegmann C., Worsch U., Maasberg M., Havemann K. Production of immunoreactive insulin-like growth factor I and response to exogenous IGF-I in small cell lung cancer cell lines. Exp Cell Res. 1988 Jun;176(2):336–343. doi: 10.1016/0014-4827(88)90335-7. [DOI] [PubMed] [Google Scholar]
  81. Jordan V. C. Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen. J Natl Cancer Inst. 1990 Nov 7;82(21):1662–1663. doi: 10.1093/jnci/82.21.1662. [DOI] [PubMed] [Google Scholar]
  82. Kaleko M., Rutter W. J., Miller A. D. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol. 1990 Feb;10(2):464–473. doi: 10.1128/mcb.10.2.464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Katzenellenbogen B. S., Norman M. J. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology. 1990 Feb;126(2):891–898. doi: 10.1210/endo-126-2-891. [DOI] [PubMed] [Google Scholar]
  84. Klapper D. G., Svoboda M. E., Van Wyk J. J. Sequence analysis of somatomedin-C: confirmation of identity with insulin-like growth factor I. Endocrinology. 1983 Jun;112(6):2215–2217. doi: 10.1210/endo-112-6-2215. [DOI] [PubMed] [Google Scholar]
  85. Kohn E. C., Francis E. A., Liotta L. A., Schiffmann E. Heterogeneity of the motility responses in malignant tumor cells: a biological basis for the diversity and homing of metastatic cells. Int J Cancer. 1990 Aug 15;46(2):287–292. doi: 10.1002/ijc.2910460225. [DOI] [PubMed] [Google Scholar]
  86. Kull F. C., Jr, Jacobs S., Su Y. F., Svoboda M. E., Van Wyk J. J., Cuatrecasas P. Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem. 1983 May 25;258(10):6561–6566. [PubMed] [Google Scholar]
  87. Kurihara M., Tokunaga Y., Tsutsumi K., Kawaguchi T., Shigematsu K., Niwa M., Mori K. Characterization of insulin-like growth factor I and epidermal growth factor receptors in meningioma. J Neurosurg. 1989 Oct;71(4):538–544. doi: 10.3171/jns.1989.71.4.0538. [DOI] [PubMed] [Google Scholar]
  88. Kvols L. K., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J., Hahn R. G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986 Sep 11;315(11):663–666. doi: 10.1056/NEJM198609113151102. [DOI] [PubMed] [Google Scholar]
  89. Lamberts S. W., Uitterlinden P., del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab. 1987 Oct;65(4):703–710. doi: 10.1210/jcem-65-4-703. [DOI] [PubMed] [Google Scholar]
  90. Lammers R., Gray A., Schlessinger J., Ullrich A. Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J. 1989 May;8(5):1369–1375. doi: 10.1002/j.1460-2075.1989.tb03517.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Lamson G., Oh Y., Pham H., Giudice L. C., Rosenfeld R. G. Expression of two insulin-like growth factor-binding proteins in a human endometrial cancer cell line: structural, immunological, and genetic characterization. J Clin Endocrinol Metab. 1989 Oct;69(4):852–859. doi: 10.1210/jcem-69-4-852. [DOI] [PubMed] [Google Scholar]
  92. Lee Y. L., Hintz R. L., James P. M., Lee P. D., Shively J. E., Powell D. R. Insulin-like growth factor (IGF) binding protein complementary deoxyribonucleic acid from human HEP G2 hepatoma cells: predicted protein sequence suggests an IGF binding domain different from those of the IGF-I and IGF-II receptors. Mol Endocrinol. 1988 May;2(5):404–411. doi: 10.1210/mend-2-5-404. [DOI] [PubMed] [Google Scholar]
  93. Little M. H., Ablett G., Smith P. J. Enhanced expression of insulin-like growth factor II is not a necessary event in Wilms' tumour progression. Carcinogenesis. 1987 Jun;8(6):865–868. doi: 10.1093/carcin/8.6.865. [DOI] [PubMed] [Google Scholar]
  94. Little M., Van Heyningen V., Hastie N. Dads and disomy and disease. Nature. 1991 Jun 20;351(6328):609–610. doi: 10.1038/351609a0. [DOI] [PubMed] [Google Scholar]
  95. MacDonald R. G., Pfeffer S. R., Coussens L., Tepper M. A., Brocklebank C. M., Mole J. E., Anderson J. K., Chen E., Czech M. P., Ullrich A. A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. Science. 1988 Mar 4;239(4844):1134–1137. doi: 10.1126/science.2964083. [DOI] [PubMed] [Google Scholar]
  96. Macaulay V. M., Everard M. J., Teale J. D., Trott P. A., Van Wyk J. J., Smith I. E., Millar J. L. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res. 1990 Apr 15;50(8):2511–2517. [PubMed] [Google Scholar]
  97. Macaulay V. M., Teale J. D., Everard M. J., Joshi G. P., Millar J. L., Smith I. E. Serum insulin-like growth factor-I levels in patients with small cell lung cancer. Eur J Cancer Clin Oncol. 1988 Jul;24(7):1241–1242. doi: 10.1016/0277-5379(88)90135-6. [DOI] [PubMed] [Google Scholar]
  98. Marquardt H., Todaro G. J., Henderson L. E., Oroszlan S. Purification and primary structure of a polypeptide with multiplication-stimulating activity from rat liver cell cultures. Homology with human insulin-like growth factor II. J Biol Chem. 1981 Jul 10;256(13):6859–6865. [PubMed] [Google Scholar]
  99. Massagué J., Czech M. P. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem. 1982 May 10;257(9):5038–5045. [PubMed] [Google Scholar]
  100. Minuto F., Barreca A., Del Monte P., Cariola G., Torre G. C., Giordano G. Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. J Clin Endocrinol Metab. 1989 Mar;68(3):621–626. doi: 10.1210/jcem-68-3-621. [DOI] [PubMed] [Google Scholar]
  101. Minuto F., Del Monte P., Barreca A., Alama A., Cariola G., Giordano G. Evidence for autocrine mitogenic stimulation by somatomedin-C/insulin-like growth factor I on an established human lung cancer cell line. Cancer Res. 1988 Jul 1;48(13):3716–3719. [PubMed] [Google Scholar]
  102. Minuto F., Del Monte P., Barreca A., Fortini P., Cariola G., Catrambone G., Giordano G. Evidence for an increased somatomedin-C/insulin-like growth factor I content in primary human lung tumors. Cancer Res. 1986 Feb;46(2):985–988. [PubMed] [Google Scholar]
  103. Morgan D. O., Edman J. C., Standring D. N., Fried V. A., Smith M. C., Roth R. A., Rutter W. J. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature. 1987 Sep 24;329(6137):301–307. doi: 10.1038/329301a0. [DOI] [PubMed] [Google Scholar]
  104. Nakanishi Y., Mulshine J. L., Kasprzyk P. G., Natale R. B., Maneckjee R., Avis I., Treston A. M., Gazdar A. F., Minna J. D., Cuttitta F. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest. 1988 Jul;82(1):354–359. doi: 10.1172/JCI113594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Ohmura E., Okada M., Onoda N., Kamiya Y., Murakami H., Tsushima T., Shizume K. Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res. 1990 Jan 1;50(1):103–107. [PubMed] [Google Scholar]
  106. Okimura Y., Kitajima N., Uchiyama T., Yagi H., Abe H., Shakutsui S., Chihara K. Insulin-like growth factor I (IGF-I) production and the presence of IGF-I receptors in rat medullary thyroid carcinoma cell line 6-23 (clone 6). Biochem Biophys Res Commun. 1989 Jun 15;161(2):589–595. doi: 10.1016/0006-291x(89)92640-5. [DOI] [PubMed] [Google Scholar]
  107. Oshima A., Nolan C. M., Kyle J. W., Grubb J. H., Sly W. S. The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells. J Biol Chem. 1988 Feb 15;263(5):2553–2562. [PubMed] [Google Scholar]
  108. Pavelić K., Vrbanec D., Marusić S., Levanat S., Cabrijan T. Autocrine tumour growth regulation by somatomedin C: an in-vitro model. J Endocrinol. 1986 May;109(2):233–238. doi: 10.1677/joe.0.1090233. [DOI] [PubMed] [Google Scholar]
  109. Pekonen F., Partanen S., Mäkinen T., Rutanen E. M. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res. 1988 Mar 1;48(5):1343–1347. [PubMed] [Google Scholar]
  110. Pekonen F., Partanen S., Rutanen E. M. Binding of epidermal growth factor and insulin-like growth-factor I in renal carcinoma and adjacent normal kidney tissue. Int J Cancer. 1989 Jun 15;43(6):1029–1033. doi: 10.1002/ijc.2910430612. [DOI] [PubMed] [Google Scholar]
  111. Peyrat J. P., Bonneterre J., Beuscart R., Djiane J., Demaille A. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res. 1988 Nov 15;48(22):6429–6433. [PubMed] [Google Scholar]
  112. Pierson R. W., Jr, Temin H. M. The partial purification from calf serum of a fraction with multiplication-stimulating activity for chicken fibroblasts in cell culture and with non-suppressible insulin-like activity. J Cell Physiol. 1972 Jun;79(3):319–330. doi: 10.1002/jcp.1040790302. [DOI] [PubMed] [Google Scholar]
  113. Pollak M. N., Perdue J. F., Margolese R. G., Baer K., Richard M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett. 1987 Dec;38(1-2):223–230. doi: 10.1016/0304-3835(87)90218-7. [DOI] [PubMed] [Google Scholar]
  114. Pollak M. N., Polychronakos C., Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res. 1989 Jul-Aug;9(4):889–891. [PubMed] [Google Scholar]
  115. Pollak M. N., Polychronakos C., Yousefi S., Richard M. Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun. 1988 Jul 15;154(1):326–331. doi: 10.1016/0006-291x(88)90688-2. [DOI] [PubMed] [Google Scholar]
  116. Pollak M., Costantino J., Polychronakos C., Blauer S. A., Guyda H., Redmond C., Fisher B., Margolese R. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst. 1990 Nov 7;82(21):1693–1697. doi: 10.1093/jnci/82.21.1693. [DOI] [PubMed] [Google Scholar]
  117. Pollak M., Richard M. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst. 1990 Aug 15;82(16):1349–1352. doi: 10.1093/jnci/82.16.1349. [DOI] [PubMed] [Google Scholar]
  118. Rechler M. M., Nissley S. P. Insulin-like growth factor (IGF)/somatomedin receptor subtypes: structure, function, and relationships to insulin receptors and IGF carrier proteins. Horm Res. 1986;24(2-3):152–159. doi: 10.1159/000180554. [DOI] [PubMed] [Google Scholar]
  119. Reeve A. E., Eccles M. R., Wilkins R. J., Bell G. I., Millow L. J. Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature. 1985 Sep 19;317(6034):258–260. doi: 10.1038/317258a0. [DOI] [PubMed] [Google Scholar]
  120. Reeve J. G., Payne J. A., Bleehen N. M. Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours. Br J Cancer. 1990 May;61(5):727–731. doi: 10.1038/bjc.1990.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Rinderknecht E., Humbel R. E. Primary structure of human insulin-like growth factor II. FEBS Lett. 1978 May 15;89(2):283–286. doi: 10.1016/0014-5793(78)80237-3. [DOI] [PubMed] [Google Scholar]
  122. Ritvos O., Ranta T., Jalkanen J., Suikkari A. M., Voutilainen R., Bohn H., Rutanen E. M. Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology. 1988 May;122(5):2150–2157. doi: 10.1210/endo-122-5-2150. [DOI] [PubMed] [Google Scholar]
  123. Rohlik Q. T., Adams D., Kull F. C., Jr, Jacobs S. An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture. Biochem Biophys Res Commun. 1987 Nov 30;149(1):276–281. doi: 10.1016/0006-291x(87)91635-4. [DOI] [PubMed] [Google Scholar]
  124. Rom W. N., Basset P., Fells G. A., Nukiwa T., Trapnell B. C., Crysal R. G. Alveolar macrophages release an insulin-like growth factor I-type molecule. J Clin Invest. 1988 Nov;82(5):1685–1693. doi: 10.1172/JCI113781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Ron D., Powers A. C., Pandian M. R., Godine J. E., Axelrod L. Increased insulin-like growth factor II production and consequent suppression of growth hormone secretion: a dual mechanism for tumor-induced hypoglycemia. J Clin Endocrinol Metab. 1989 Apr;68(4):701–706. doi: 10.1210/jcem-68-4-701. [DOI] [PubMed] [Google Scholar]
  126. Ross M., Francis G. L., Szabo L., Wallace J. C., Ballard F. J. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J. 1989 Feb 15;258(1):267–272. doi: 10.1042/bj2580267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Roth R. A. Structure of the receptor for insulin-like growth factor II: the puzzle amplified. Science. 1988 Mar 11;239(4845):1269–1271. doi: 10.1126/science.2964085. [DOI] [PubMed] [Google Scholar]
  128. Ruggeri B. A., Klurfeld D. M., Kritchevsky D., Furlanetto R. W. Caloric restriction and 7,12-dimethylbenz(a)anthracene-induced mammary tumor growth in rats: alterations in circulating insulin, insulin-like growth factors I and II, and epidermal growth factor. Cancer Res. 1989 Aug 1;49(15):4130–4134. [PubMed] [Google Scholar]
  129. Russell W. E., Van Wyk J. J., Pledger W. J. Inhibition of the mitogenic effects of plasma by a monoclonal antibody to somatomedin C. Proc Natl Acad Sci U S A. 1984 Apr;81(8):2389–2392. doi: 10.1073/pnas.81.8.2389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Rutanen E. M., Pekonen F., Mäkinen T. Soluble 34K binding protein inhibits the binding of insulin-like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. J Clin Endocrinol Metab. 1988 Jan;66(1):173–180. doi: 10.1210/jcem-66-1-173. [DOI] [PubMed] [Google Scholar]
  131. SALMON W. D., Jr, DAUGHADAY W. H. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 1957 Jun;49(6):825–836. [PubMed] [Google Scholar]
  132. Schally A. V. Oncological applications of somatostatin analogues. Cancer Res. 1988 Dec 15;48(24 Pt 1):6977–6985. [PubMed] [Google Scholar]
  133. Schofield P. N., Connor H., Turner R. C., Zapf J. Tumour hypoglycaemia: raised tumour IGFII mRNA associated with reduced plasma somatomedins. Br J Cancer. 1989 Nov;60(5):661–663. doi: 10.1038/bjc.1989.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Scott J., Cowell J., Robertson M. E., Priestley L. M., Wadey R., Hopkins B., Pritchard J., Bell G. I., Rall L. B., Graham C. F. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature. 1985 Sep 19;317(6034):260–262. doi: 10.1038/317260a0. [DOI] [PubMed] [Google Scholar]
  135. Shapiro E. T., Bell G. I., Polonsky K. S., Rubenstein A. H., Kew M. C., Tager H. S. Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II. J Clin Invest. 1990 May;85(5):1672–1679. doi: 10.1172/JCI114619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Shigematsu K., Kataoka Y., Kamio T., Kurihara M., Niwa M., Tsuchiyama H. Partial characterization of insulin-like growth factor I in primary human lung cancers using immunohistochemical and receptor autoradiographic techniques. Cancer Res. 1990 Apr 15;50(8):2481–2484. [PubMed] [Google Scholar]
  137. Snyder J. M., D'Ercole A. J. Somatomedin C/insulin-like growth factor I production by human fetal lung tissue maintained in vitro. Exp Lung Res. 1987;13(4):449–458. doi: 10.3109/01902148709069604. [DOI] [PubMed] [Google Scholar]
  138. Sporn M. B., Todaro G. J. Autocrine secretion and malignant transformation of cells. N Engl J Med. 1980 Oct 9;303(15):878–880. doi: 10.1056/NEJM198010093031511. [DOI] [PubMed] [Google Scholar]
  139. Stege R., Fröhlander N., Carlström K., Pousette A., von Schoultz B. Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: effects of parenteral and oral estrogen therapy. Prostate. 1987;10(4):333–338. doi: 10.1002/pros.2990100407. [DOI] [PubMed] [Google Scholar]
  140. Stracke M. L., Engel J. D., Wilson L. W., Rechler M. M., Liotta L. A., Schiffmann E. The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J Biol Chem. 1989 Dec 25;264(36):21544–21549. [PubMed] [Google Scholar]
  141. Su T. S., Liu W. Y., Han S. H., Jansen M., Yang-Fen T. L., P'eng F. K., Chou C. K. Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res. 1989 Apr 1;49(7):1773–1777. [PubMed] [Google Scholar]
  142. Talavera F., Reynolds R. K., Roberts J. A., Menon K. M. Insulin-like growth factor I receptors in normal and neoplastic human endometrium. Cancer Res. 1990 May 15;50(10):3019–3024. [PubMed] [Google Scholar]
  143. Thompson M. A., Cox A. J., Whitehead R. H., Jonas H. A. Autocrine regulation of human tumor cell proliferation by insulin-like growth factor II: an in-vitro model. Endocrinology. 1990 Jun;126(6):3033–3042. doi: 10.1210/endo-126-6-3033. [DOI] [PubMed] [Google Scholar]
  144. Tricoli J. V., Rall L. B., Karakousis C. P., Herrera L., Petrelli N. J., Bell G. I., Shows T. B. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res. 1986 Dec;46(12 Pt 1):6169–6173. [PubMed] [Google Scholar]
  145. Ullrich A., Gray A., Tam A. W., Yang-Feng T., Tsubokawa M., Collins C., Henzel W., Le Bon T., Kathuria S., Chen E. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986 Oct;5(10):2503–2512. doi: 10.1002/j.1460-2075.1986.tb04528.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Van Schravendijk C. F., Foriers A., Van den Brande J. L., Pipeleers D. G. Evidence for the presence of type I insulin-like growth factor receptors on rat pancreatic A and B cells. Endocrinology. 1987 Nov;121(5):1784–1788. doi: 10.1210/endo-121-5-1784. [DOI] [PubMed] [Google Scholar]
  147. Van Wyk J. J., Graves D. C., Casella S. J., Jacobs S. Evidence from monoclonal antibody studies that insulin stimulates deoxyribonucleic acid synthesis through the type I somatomedin receptor. J Clin Endocrinol Metab. 1985 Oct;61(4):639–643. doi: 10.1210/jcem-61-4-639. [DOI] [PubMed] [Google Scholar]
  148. Verland S., Gammeltoft S. Functional receptors for insulin-like growth factors I and II in rat thymocytes and mouse thymoma cells. Mol Cell Endocrinol. 1989 Dec;67(2-3):207–216. doi: 10.1016/0303-7207(89)90211-6. [DOI] [PubMed] [Google Scholar]
  149. WIEDEMANN H. R. COMPLEXE MALFORMATIF FAMILIAL AVEC HERNIE OMBILICALE ET MACROGLOSSIE--UN "SYNDROME NOUVEAU"? J Genet Hum. 1964 Sep;13:223–232. [PubMed] [Google Scholar]
  150. Weima S. M., Stet L. H., van Rooijen M. A., van Buul-Offers S. C., van Zoelen E. J., de Laat S. W., Mummery C. L. Human teratocarcinoma cells express functional insulin-like growth factor I receptors. Exp Cell Res. 1989 Oct;184(2):427–439. doi: 10.1016/0014-4827(89)90341-8. [DOI] [PubMed] [Google Scholar]
  151. Whitehead R. H., Novak U., Thomas R. J., Lukeis R. E., Walker F. E., Jones J. A new gastric carcinoma cell line (LIM1839) derived from a young Caucasian male. Int J Cancer. 1989 Dec 15;44(6):1100–1103. doi: 10.1002/ijc.2910440627. [DOI] [PubMed] [Google Scholar]
  152. Widmer U., Zapf J., Froesch E. R. Is extrapancreatic tumor hypoglycemia associated with elevated levels of insulin-like growth factor II? J Clin Endocrinol Metab. 1982 Nov;55(5):833–839. doi: 10.1210/jcem-55-5-833. [DOI] [PubMed] [Google Scholar]
  153. Williams D. W., Williams E. D., Wynford-Thomas D. Evidence for autocrine production of IGF-1 in human thyroid adenomas. Mol Cell Endocrinol. 1989 Jan;61(1):139–143. doi: 10.1016/0303-7207(89)90199-8. [DOI] [PubMed] [Google Scholar]
  154. Willison K. Opposite imprinting of the mouse Igf2 and Igf2r genes. Trends Genet. 1991 Apr;7(4):107–109. doi: 10.1016/0168-9525(91)90441-r. [DOI] [PubMed] [Google Scholar]
  155. Yashiro T., Ohba Y., Murakami H., Obara T., Tsushima T., Fujimoto Y., Shizume K., Ito K. Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. Acta Endocrinol (Copenh) 1989 Jul;121(1):112–120. doi: 10.1530/acta.0.1210112. [DOI] [PubMed] [Google Scholar]
  156. Yee D., Paik S., Lebovic G. S., Marcus R. R., Favoni R. E., Cullen K. J., Lippman M. E., Rosen N. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989 Mar;3(3):509–517. doi: 10.1210/mend-3-3-509. [DOI] [PubMed] [Google Scholar]
  157. Zapf J., Froesch E. R. Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role. Horm Res. 1986;24(2-3):121–130. doi: 10.1159/000180551. [DOI] [PubMed] [Google Scholar]
  158. van Buul-Offers S., Ueda I., Van den Brande J. L. Biosynthetic somatomedin C (SM-C/IGF-I) increases the length and weight of Snell dwarf mice. Pediatr Res. 1986 Sep;20(9):825–827. doi: 10.1203/00006450-198609000-00002. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES